ACACIA PHARMA TO ANNOUNCE ITS RESULTS FOR THE FULL YEAR 2018 ON WEDNESDAY 27 FEBRUARY
Cambridge, UK and Indianapolis, US – 25 February 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, will announce its results for the full year ended 31 December 2018 on Wednesday 27 February. A conference call will take place at 3:00pm CET on the same day and the presentation will be available on the company’s website in the Investors section (Financial Reports and Presentations) shortly before.
To join the conference call, please dial in 5-10 minutes prior to the start using the phone numbers and password provided below.
Standard International Access +44 (0) 20 3003 2666
UK Toll Free
Belgium Toll Free
USA Toll Free
Conference password
Contacts
Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
acaciapharma@
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group's lead project, BARHEMSYS™ for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies. A New Drug Application (NDA) for BARHEMSYS is under review by the US Food and Drug Administration (FDA). Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com